Krystal Biotech Stock
Krystal Biotech Stock
The Krystal Biotech stock is trending slightly upwards today, with an increase of €0.70 (0.330%) compared to yesterday's price.
With 22 Buy predictions and not a single Sell prediction Krystal Biotech is an absolute favorite of our community.
However, we have a potential of -0.77% for Krystal Biotech as the target price of 207 € is below the current price of 208.6 €.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Krystal Biotech stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Krystal Biotech in the next few years
Pros
?
G***** c******* t* c**********
?
M***** P*******
?
B****
Cons
?
S********** s********
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Krystal Biotech vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Krystal Biotech | 0.330% | 3.678% | 18.962% | 25.776% | 37.057% | 193.803% | - |
| Ardelyx Inc. | 5.570% | 2.840% | 1.187% | 5.509% | 6.465% | 176.349% | -3.856% |
| Evolus Inc | -4.200% | -1.724% | -8.065% | -47.706% | -45.714% | -18.571% | 88.742% |
| Champions Oncology Inc | -1.940% | 0.000% | -15.833% | -13.675% | 6.092% | -19.200% | -45.109% |
Comments
Krystal Biotech (NASDAQ:KRYS) had its price target raised by analysts at Chardan Capital from $216.00 to $220.00. They now have a "buy" rating on the stock.
Show more
Ratings data for KRYS provided by MarketBeat
The comment is under review
Krystal Biotech (NASDAQ:KRYS) had its price target raised by analysts at Bank of America Corporation from $182.00 to $255.00. They now have a "buy" rating on the stock.
Show more
Ratings data for KRYS provided by MarketBeat